Novo Nordisk(US:NVO) GLP1减重宝典·2025-10-23 11:49Core Viewpoint - The article discusses the rise of GLP-1 receptor agonists, particularly semaglutide (Ozempic and Wegovy), as effective treatments for type 2 diabetes and obesity, highlighting their popularity driven by social media and celebrity endorsements [4][6][10]. Group 1: Drug Development and Approval Timeline - The first GLP-1 drug, liraglutide (Victoza), was approved by the FDA in 2010 for blood sugar control in diabetes patients [6]. - Semaglutide was introduced in 2017 as Ozempic, initially for type 2 diabetes, and later as Wegovy for obesity in 2021, showing an average weight loss of about 15% after one year of use [6][16]. - The FDA approved semaglutide for weight management in 2021, and it was included in China's National Medical Insurance Directory in 2021 [16]. Group 2: Market Impact and Popularity - Since 2022, semaglutide has gained immense popularity, becoming known as a "celebrity weight loss injection" due to endorsements from figures like Elon Musk and Donald Trump [7][10]. - The demand for Wegovy surged, leading to shortages of both Wegovy and its sister product Ozempic, which is primarily used for diabetes treatment [10][12]. - Social media platforms have seen millions of views on content related to the weight loss effects of semaglutide, indicating a significant public interest [10][12]. Group 3: Mechanism of Action - GLP-1 is a hormone that helps lower blood sugar levels by promoting insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying, which also contributes to weight control [30]. - The development of GLP-1 receptor agonists is based on the observation that both diabetic and non-diabetic obese patients have reduced GLP-1 secretion and action [30][31]. Group 4: Usage Guidelines and Side Effects - Semaglutide is available in both injectable and oral forms, with specific dosing guidelines for initiation and maintenance [19][22]. - Common side effects include gastrointestinal issues such as nausea and vomiting, which may decrease as the body adjusts to the medication [28].